 |
Minimale Einzahlung $50 Exklusive Aktion |
Unser Ergebnis |
0% Kommission |
Are you looking to buy Matinas BioPharma stocks? Chech our Reportlab with an in-depth review, check prices, statistics and see if buying this stock is interesting right now. This article will help you buy AMEX:MTNB! and analyze the company to see if this stock might be an interesting option to invest in. We will enlighten you about Matinas BioPharma stocks and how to buy and use them. Click on the button to start reading the review right now or scroll down for real time statistics about this company.
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nano-crystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT9001, a prescription-only omega-3 free fatty acid formulation for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Neurological Disorders and Stroke (NINDS) for the development of a novel therapy for the treatment of HIV, as well as with ViiV Healthcare to develop and evaluate formulations of antiviral drug candidates; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was founded in 2013 and is based in Bedminster, New Jersey.
Durchschnittliches Volumen
8.16 million shs
MARKTKAPPE
$267.25 million
Börse
NYSEAMERICAN
Kaufen Sie diese Aktie!
|
NAME
|
TICKER
|
INDUSTRIE
|
SECTOR
|
VOLUME
|
KAUFEN SIE DIESE AKTIE JETZT
|
|---|---|---|---|---|---|
|
AMEX:MTNB
|
Pharmazeutische Präparate
|
Medizinisch
|
146,141 shs
|
Below is a quick guide on how to buy AMEX:MTNB stocks safe, fast and around the world in less than five minutes.
Schritt 1: Eröffnen Sie ein Konto bei eToro – eToro is the best broker to buy Matinas BioPharma shares in the world as you won’t pay any commissions. To do this, visit the eToro website and open an account, it is 100% safe and they offer a huge amount of stocks.
Schritt 2: Laden Sie Ihre ID hoch - Gemäß den KYC-Vorschriften wird eToro Sie bitten, eine Kopie Ihres Reisepasses oder Führerscheins hochzuladen.
Schritt 3: Geld einzahlen - Zahlen Sie etwas Geld auf Ihr neu eingerichtetes eToro Konto ein. Sie können zwischen Banküberweisung, E-Wallet, Debit-/Kreditkarte oder Paypal wählen.
Schritt 4: Buy Matinas BioPharma – Search for “”AMEX:MTNB”” and click on the “”Trade”” button. Enter the total amount of your investment (minimum $50) and confirm the order by clicking the “”Open Trade”” button. And that’s it: you have just bought Matinas BioPharma stocks with 0% commission!.
1 | | Minimale Einzahlung $50 Exklusive Aktion | Unser Ergebnis 10 ★★★★★ | 0% Kommission |
4 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Matinas BioPharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should “buy” Matinas BioPharma stock.
Wall Street analysts have given Matinas BioPharma a “Buy” rating, but there may be better short-term opportunities in the market. Some of Reportlab’s past winning trading ideas have resulted in 5-15% weekly gains. Reportlab just released five new trading ideas, but Matinas BioPharma wasn’t one of them. Reportlab thinks five stocks may be even better buys in the how to buy stocks guide.
1 | | Minimale Einzahlung $50 Exklusive Aktion | Unser Ergebnis 10 ★★★★★ | 0% Kommission |
2 |  | Minimale Einzahlung $50 Exklusive Aktion | Unser Ergebnis 10 ★★★★★ | 0% Kommission |
3 |  | Minimale Einzahlung $50 Exklusive Aktion | Unser Ergebnis 10 ★★★★★ | 0% Kommission |
It can be difficult to navigate through all the outdated and incorrect information related to purchasing AMEX:MTNB stocks. We believe that stocks should be accessible for all, which is why we’ve created this handy guide on where to buy Matinas BioPharma stocks with a step by step approach.
You’ll need to register with a broker, in these times you can’t go without once and it’s crucial to use a regulated broker that’s allowed to operate there, otherwise, you risk losing funds. eToro is one such broker, and one of the best brokers to buy Matinas BioPharma stocks with 0% comission, to sign up just click on open account in the following table or compare other options.
Da es sich bei eToro um eine regulierte Plattform handelt, müssen Sie das KYC-Verfahren abschließen. Dies ist gängige Praxis und dauert nur ein paar Minuten. Sie müssen einen Lichtbildausweis (Reisepass, Führerschein) und einen Adressnachweis (Stromrechnung, Kontoauszug) vorlegen.
Sobald Sie sich angemeldet und Ihr Konto verifiziert haben, müssen Sie Geld einzahlen. eToro akzeptiert Kredit-/Debitkarten, Banküberweisungen und auch E-Wallets. Was auch immer Sie bevorzugen, es wird etwas für Sie dabei sein.
Now that you’ve funded your eToro account, just type “AMEX:MTNB stocks" in die Suchleiste am oberen Rand des Bildschirms ein und drücken Sie auf "Handeln".
All that’s left is to buy some AMEX:MTNB stock. Simply enter the amount you want to purchase and hit the “buy” button. The amount you bought will be automatically credited to your account where you can monitor its performance.
All in all, AMEX:MTNB is an incredibly interesting company that has the potential to solve some major issues in the business space. After reading this guide you should know how to buy this investment using the best broker or platform. We recommend eToro to anyone looking for a regulated, easy-to-use, fully-featured broker to buy Matinas BioPharma stocks. As with any broker or online platform, it’s crucial you set up 2FA when using their tools as it ensures your funds are completely safe.
Matinas BioPharma is scheduled to release its next quarterly earnings announcement on Monday, March 8th 2021.
View our earnings forecast for Matinas BioPharma.
Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) issued its earnings results on Friday, November, 6th. The company reported ($0.03) earnings per share for the quarter, meeting the consensus estimate of ($0.03). The business had revenue of $0.10 million for the quarter, compared to analysts’ expectations of $0.06 million.
View Matinas BioPharma’s earnings history.
4 equities research analysts have issued 12 month price targets for Matinas BioPharma’s shares. Their forecasts range from $3.00 to $4.00. On average, they expect Matinas BioPharma’s stock price to reach $3.63 in the next twelve months. This suggests a possible upside of 197.1% from the stock’s current price.
View analysts’ price targets for Matinas BioPharma or view top-rated stocks among Wall Street analysts.
Matinas BioPharma’s management team includes the following people:
Mr. Jerome D. Jabbour J.D., Co-Founder, CEO, Pres & Director (Age 47, Pay $644.79k)
Mr. Keith A. Kucinski CPA, M.B.A., Chief Financial Officer (Age 51, Pay $249.05k)
Dr. Theresa Matkovits, Chief Devel. Officer (Age 54, Pay $380.62k)
Dr. James J. Ferguson, Chief Medical Officer (Age 68, Pay $490.85k)
Dr. Hui Liu M.B.A., Ph.D., Chief Technology Officer (Age 54)
Dr. Raphael J. Mannino, Chief Scientific Officer (Age 74)
Ian Cooney, Director of Investor Relations & Corp. Devel.
Mr. Frank Calamusa, Exec. Director and Head of Manufacturing & Supply Chain
Launched in 2006, eToro is, in our opinion, without a doubt the best broker for buying AMEX:MTNB stocks in the world. The onboarding process is simple, it’s designed to make sure even those new to the stock market are ready to start investing the shortest amount of time possible. As a regulated platform you gain several benefits, most importantly, you know they’re not going to run off with your hard-earned money./
Mehr als 95% der Kundengelder werden offline, in kalten Lagern, aufbewahrt, was für jeden Broker, der Ihr Vermögen verwaltet, entscheidend ist. Unabhängig davon, wie sicher eine Plattform sein soll, empfehlen wir die Verwendung von 2FA, um eine zusätzliche Sicherheitsebene für Ihr Konto zu schaffen.
eToro bietet Nutzern eine Reihe von Funktionen, um so schnell wie möglich mit dem Investieren zu beginnen. Es gibt eine relativ einzigartige Funktion namens Copy Trading, mit der Sie ein passives Einkommen erzielen können, indem Sie erfahrene Händler spiegeln. So können Sie schnell Gewinne erzielen und erhalten ein besseres Verständnis für die Strategien, die von Profis verwendet werden. Außerdem können Sie bei eToro in verwaltete Portfolios investieren. Ein verwaltetes Portfolio besteht aus einer Vielzahl ähnlicher Vermögenswerte, die in Gruppen zusammengefasst sind. Wenn Sie bereits über Handelserfahrung verfügen, können Sie auch in andere Märkte als Aktien investieren, da eToro den Handel mit ETFs, Rohstoffen, Kryptowährungen und Indizes ermöglicht. Wenn Sie bereits außerhalb des Aktienmarktes investieren, kann dies sehr nützlich sein, da Sie so alle Ihre Investitionen an einem einzigen Ort verwalten können.
Some companies that are related to Matinas BioPharma include Cara Therapeutics (CARA), Esperion Therapeutics (ESPR), Dyne Therapeutics (DYN), Annexon (ANNX), Vectura Group (VEGPF), VBI Vaccines (VBIV), Kadmon (KDMN), Amphastar Pharmaceuticals (AMPH), Aclaris Therapeutics (ACRS), Phibro Animal Health (PAHC), Protagonist Therapeutics (PTGX), Collegium Pharmaceutical (COLL), Provention Bio (PRVB), Vanda Pharmaceuticals (VNDA) and Clovis Oncology (CLVS).
View all of MTNB’s competitors.
Based on aggregate information from Reportlab, some companies that other Matinas BioPharma investors own include KushCo (KSHB), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), Cannabics Pharmaceuticals (CNBX), OrganiGram (OGI), Novan (NOVN), Zosano Pharma (ZSAN) and Aeterna Zentaris (AEZS).
CFDs sind komplexe Instrumente und bergen aufgrund der Hebelwirkung ein hohes Risiko, schnell Geld zu verlieren. 68% der Konten von Kleinanlegern verlieren Geld beim Handel mit CFDs bei diesem Anbieter. Sie sollten sich überlegen, ob Sie verstehen, wie CFDs funktionieren und ob Sie das hohe Risiko, Ihr Geld zu verlieren, eingehen können.
Matinas BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol “MTNB.”
Matinas BioPharma’s stock is owned by a number of retail and institutional investors. Top institutional investors include Victory Capital Management Inc. (0.51%) and MONECO Advisors LLC (0.03%). Company insiders that own Matinas BioPharma stock include Adam K Stern, Herbert J Conrad, Jerome D Jabbour, Keith A Kucinski and Patrick G Lepore.
View institutional ownership trends for Matinas BioPharma.
MTNB stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., and MONECO Advisors LLC.
View insider buying and selling activity for Matinas BioPharma or view top insider-selling stocks.
Shares of MTNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Vergleichen Sie hier die Top-Broker.
1 | | Minimale Einzahlung $50 Exklusive Aktion | Unser Ergebnis 10 ★★★★★ | 0% Kommission |
One share of MTNB stock can currently be purchased for approximately $1.22.
Matinas BioPharma has a market capitalization of $243.32 million and generates $90,000.00 in revenue each year. The company earns $-17,370,000.00 in net income (profit) each year or ($0.13) on an earnings per share basis.
Matinas BioPharma employs 21 workers across the globe.
The official website for Matinas BioPharma is www.matinasbiopharma.com.
Matinas BioPharma is headquartered at SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States.
Matinas BioPharma’s mailing address is SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States. The company can be reached via phone at +1-908-4431860 or via email at mtnb@jtcir.com
Wir von Reportlab.org möchten sicherstellen, dass Sie alle wichtigen Informationen über Aktien kaufen. Wir bieten Ihnen die besten Leitfäden zum Thema Börse mit persönlichen Bewertungen, Hintergrundinformationen, Plattformbewertungen, Anleitungen und mehr. Möchten Sie weitere Informationen erhalten? Dann schauen Sie sich die OTC-Aktien, NASDAQ-Aktien, NYSE-Aktien, LON-Aktien, FRA-Aktien, ETR-Aktien, EPA-Bestände, TSX-Aktien oder Amex Aktien. Sie suchen nach detaillierteren Informationen wie 5g Vorräte, Biotech-Aktien, Goldvorräte und andere Informationen aus unserem Reportlab.
How can you buy Matinas BioPharma stock on the internet?
You can easily buy Matinas BioPharma stocks with one of the well known regulated brokers on the internet. You can open an account within 5 minutes, make deposits with countless payment providers and trade with professional tools on their platform. At the moment, our visitors rate eToro as the most popular choice.
Eine weitere Option ist die Nutzung eines regulierten Brokers wie IC-Märkte oder Interaktive Makler. You can an account with these brokers and start buying or trading AMEX:MTNB stocks in a safe and complete environment to trade in.
Where to buy Matinas BioPharma stock?
You will first want to find a licensed broker that supports AMEX:MTNB stock. One of our favourite brokers, eToro for example, allows you to make investments into this asset from just $25 and only charges you the spread. Another option is using a regulated broker like DEGIRO or Interactive Brokers. You can open an account with these brokers and start buying or trading AMEX:MTNB stocks in a safe and complete environment.
Is AMEX:MTNB stock a good investment?
As with any other asset, there is an element of risk associated with buying AMEX:MTNB stocks. Therefore, you will want to study the market and make a decision based on your financial standing and the risk you are willing to take.
Is Matinas BioPharma stock safe to invest in?
All stocks are volatile, or affected by market circumstances. The case with AMEX:MTNB is no different, with its price fluctuating dramatically within short periods. As such, if the market goes against you, then you will end up facing a loss. We advice you to do research first before investing in Matinas BioPharma stock.
How do you trade Matinas BioPharma stocks?
You can trade stocks by first opening an account with a regulated platform and making a deposit in US dollars, EUROs or other currency. Next, search for Matinas BioPharma stock and choose from a buy or sell order – depending on whether you think the stock asset will rise or fall in value. If you speculated on AMEX:MTNB stocks correctly, you will have made a profit. The size of your trading profit will ultimately be determined by your stake and at what percentage your position grew.
How to sell Matinas BioPharma stock?
To sell your AMEX:MTNB stocks investment, you can sign in to your broker account and cash out directly from within your portfolio. If you have stored the stocks elsewhere, you will first have to transfer them to a third-party provider or broker to cash out.
What is the best Matinas BioPharma stock trading platform?
eToro, is a top-rated platform for beginners, albeit, it charges significantly lower fees. For example, there are no fees to deposit with a debit/credit card and you only need to cover the spread when trading AMEX:MTNB stock.
Stephen kennt sich gut mit Finanzprodukten aus und hat insbesondere eine große Leidenschaft für die Aktienmärkte und ihre Teilnehmer. Wir hoffen, dass die bereitgestellten Informationen Ihnen helfen werden. Ist Ihnen etwas nicht ganz klar? Bitte hinterlassen Sie Ihre Fragen oder Kommentare unten auf der Seite.
| Unser Ergebnis ★★★★★ | |
| Unser Ergebnis ★★★★★ | |
| Unser Ergebnis ★★★★★ |
Newsletter
Neueste Nachrichten
| |
Unser Ergebnis |
0% Kommission |
Aktien & Krypto-Daten in Echtzeit
Benachrichtigungen, Tipps & Neuigkeiten
Beste Aktien & Krypto-Führer
Online Broker & Börse Bewertungen
Reportlab Finanzen ist eine rein informative Website und stellt in keinem Fall eine Anlageberatung dar. Alle Investitionen sind mit Risiken verbunden und Sie können Ihre gesamten Investitionen verlieren. Investieren Sie kein Geld, das Sie sich nicht leisten können, zu verlieren.
Reportlab Finanzen
38 Holburn Lane
Heckfield Green
IP21 0UB
Vereinigtes Königreich
Copyright © 2022 Reportlab.Finance | Alle Rechte vorbehalten.
